共 391 条
[1]
Wémeau J(2018)Graves’ disease: Introduction, epidemiology, endogenous and environmental pathogenic factors Ann Endocrinol 79 599-607
[2]
Klein M(2018)Antithyroid drug therapy: 70 years later Eur J Endocrinol 179 R261-R274
[3]
Sadoul J-L(2016)Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves’ Hyperthyroidism J Clin Endocrinol Metabolism 101 1381-1389
[4]
Briet C(2007)Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials BMJ 334 514-166
[5]
Vélayoudom-Céphise F-L(2022)Management of Graves’ hyperthyroidism: present and future Exp Rev Endocrinol Metabol 17 153-887
[6]
Burch HB(2022)TSH receptor specific monoclonal autoantibody K1-70 TM targeting of the TSH receptor in subjects with Graves’ disease and Graves’ orbitopathy—Results from a phase I clinical trial Clin Endocrinol 96 878-1028
[7]
Cooper DS(2012)Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association Endocr Pract 18 988-1751
[8]
Vos XG(2014)Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement Thyroid 24 1670-154
[9]
Endert E(2007)Therapeutic Potential for Thyroid Hormone Receptor-β Selective Agonists for Treating Obesity, Hyperlipidemia and Diabetes Current Vasc Pharmacol 5 141-70
[10]
Zwinderman AH(2022)Development of Low-Molecular-Weight Allosteric Agonist of Thyroid-Stimulating Hormone Receptor with Thyroidogenic Activity Dokl Biochem Biophys 503 67-1344